WASHINGTON — Sen. Bill Cassidy (La.), a key Republican senator with seats on the chamber’s health and finance committees, introduced a bill to let some small drugmakers avoid Medicare price negotiations.

Danish drugmaker Novo Nordisk expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive.

Results from Medicare’s first year of negotiation with other price benchmarks shed light on the competitive dynamics and payer negotiations that shape what the U.S. pays for prescription drugs.